Cyclohexyl beta-hydroxy alkyl amines and medical uses thereof
US-2024390298-A1 · Nov 28, 2024 · US
US9457009B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9457009-B2 |
| Application number | US-201313907590-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 31, 2013 |
| Priority date | May 31, 2012 |
| Publication date | Oct 4, 2016 |
| Grant date | Oct 4, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides methods for treating auditory impairments in a subject in need of treatment comprising administering to said subject an effective amount of a composition comprising, as an active agent, one or more of a carboxy alkyl ester, a quinic acid derivative, a caffeic acid derivative, a ferulic acid derivative, or a quinic acid lactone or derivative thereof or pharmaceutically acceptable salt thereof and an acceptable carrier or excipient, so as to treat auditory impairments in the subject.
Opening claim text (preview).
What is claimed is: 1. A method of treating an auditory impairment associated with cochlear outer hair cell damage, dysfunction or loss in a subject comprising administering to said subject an effective amount of a composition comprising, as an active agent, one or more of a carboxy alkyl ester selected from the group consisting of: (a) 3,4-O-dicaffeoylquinic acid, (b) 3,5-O-dicaffeoylquinic acid, (c) 1,3-O-dicaffeoylquinic acid, (d) 4,5-O-dicaffeoylquinic acid, (e) 1,5-O-dicaffeoylquinic acid, (f) 3-O-feruloylquinic acid, (g) 4-O-feruloylquinic acid, (h) 5-O-feruloylquinic acid, (i) 1-O-caffeoylquinic acid, (j) 3-O-caffeoylquinic acid, (k) 4-O-caffeoylquinic acid, (l) 5-O-caffeoylquinic acid, (m) (1S,3R,4R,5R)-3-[3-(3,4-dihydroxyphenyl)-3R-hydroxypropanoyl]-1,4,5-trihydroxycyclohexanecarboxylic acid, (n) (1S,3R,4R,5R)-3-[3-(3,4-dihydroxyphenyl)-3S-hydroxypropanoyl]-1,4,5-trihydroxycyclohexanecarboxylic acid, (o) (1S,3R,4R,5R)-5-[3-(3,4-dihydroxyphenyl)-3R-hydroxypropanoyl]-1,3,4-trihydroxycyclohexanecarboxylic acid, (p) (1S,3R,4R,5R)-5-[3-(3,4-dihydroxyphenyl)-3S-hydroxypropanoyl]-1,3,4-trihydroxycyclohexanecarboxylic acid, (q) (1S,3R,4R,5R)-4-[3-(3,4-dihydroxyphenyl)-3R-hydroxypropanoyl]-1,3,5-trihydroxycyclohexanecarboxylic acid, (r) (1S,3R,4R,5R)-4-[3-(3,4-dihydroxyphenyl)-3S-hydroxypropanoyl]-1,3,5-trihydroxycyclohexanecarboxylic acid, (s) cis-5-O-caffeoylquinic acid, (t) 3-O-caffeoylquinic acid lactone, (u) 3-O-caffeoyl-4-O-feruloylquinic acid, and (v) a pharmaceutically acceptable salt thereof, so as to restore cochlear outer hair cell function, thereby treating the auditory impairment associated with cochlear outer hair cell damage, dysfunction or loss in the subject. 2. The method of claim 1 , wherein said composition further comprises an aqueous extract from Uncaria tomentosa bark. 3. The method of claim 1 , wherein the composition is formulated for administration selected from the group consisting of auricular, oral, parenteral, intraperitoneal, local, buccal, nasal, and topical administration. 4. The method of claim 1 , wherein said composition is an aqueous extract from Uncaria tomentosa bark. 5. The method of claim 1 , wherein said composition is in the form of a liquid, tablet or capsule. 6. The method of claim 1 , wherein the auditory impairment is selected from the group consisting of permanent sensorineural hearing loss, tinnitus, loudness recruitment, hyperacusis, diplacusis and speech intelligibility deficits. 7. The method of claim 1 , wherein the active agent is less than or equal to 10,000 daltons. 8. The method of claim 2 , wherein the aqueous extract from Uncaria tomentosa bark comprises an active agent of less than or equal to 10,000 daltons. 9. The method of claim 1 , wherein cochlear outer hair cell function is sensory function as assessed by audiological tests including distortion product otoacoustic emission (DPOAE).
of acids having aromatic rings, e.g. benactizyne, clofibrate · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Lactones · CPC title
of carboxylic acids · CPC title
Rubiaceae (Madder family) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.